Case Study 2

The Discovery and Development of the Multimodal Acting Antidepressant Vortioxetine

Christoffer Bundgaard, Alan Pehrson, Connie Sánchez, Benny Bang-Andersen

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

1 Citation (Scopus)

Abstract

Vortioxetine, which was approved by the Food and Drug Administration (FDA) on September 30, 2013, for treatment of major depressive disorder (MDD) originates from the line of research aiming at an enhanced therapeutic effect compared to selective serotonin reuptake inhibitors (SSRIs) through modulation of neuroadaptive feedback mechanisms. This research led to a new class of multimodal acting antidepressants, which act via serotonin transporter (SERT ) inhibition and receptor modulation. This chapter deals with vortioxetine's discovery and development, and the impact that careful attention to engaging specific biological targets in the brain has played in its successful development. In drug discovery, in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies play a key role in ensuring that the drug-like properties and the developability potential are in place before the compound is advanced to the clinic.

Original languageEnglish
Title of host publicationBlood-Brain Barrier in Drug Discovery
Subtitle of host publicationOptimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs
Publisherwiley
Pages505-520
Number of pages16
ISBN (Electronic)9781118788523
ISBN (Print)9781118788356
DOIs
StatePublished - 2 Jan 2015

Fingerprint

Antidepressive Agents
Modulation
Serotonin Plasma Membrane Transport Proteins
Pharmacokinetics
Serotonin Receptors
Major Depressive Disorder
Serotonin Uptake Inhibitors
Therapeutic Uses
Drug Discovery
United States Food and Drug Administration
Research
Metabolism
Pharmaceutical Preparations
Brain
Feedback
vortioxetine
In Vitro Techniques
Inhibition (Psychology)

Keywords

  • Drug metabolism and pharmacokinetic (DMPK)
  • Food and Drug Administration (FDA)
  • Major depressive disorder (MDD)
  • Multimodal acting antidepressant vortioxetine
  • Selective serotonin reuptake inhibitors (SSRIs)

Cite this

Bundgaard, C., Pehrson, A., Sánchez, C., & Bang-Andersen, B. (2015). Case Study 2: The Discovery and Development of the Multimodal Acting Antidepressant Vortioxetine. In Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs (pp. 505-520). wiley. https://doi.org/10.1002/9781118788523.ch23
Bundgaard, Christoffer ; Pehrson, Alan ; Sánchez, Connie ; Bang-Andersen, Benny. / Case Study 2 : The Discovery and Development of the Multimodal Acting Antidepressant Vortioxetine. Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs. wiley, 2015. pp. 505-520
@inbook{db1ea42c4d524041ac127678751dbbea,
title = "Case Study 2: The Discovery and Development of the Multimodal Acting Antidepressant Vortioxetine",
abstract = "Vortioxetine, which was approved by the Food and Drug Administration (FDA) on September 30, 2013, for treatment of major depressive disorder (MDD) originates from the line of research aiming at an enhanced therapeutic effect compared to selective serotonin reuptake inhibitors (SSRIs) through modulation of neuroadaptive feedback mechanisms. This research led to a new class of multimodal acting antidepressants, which act via serotonin transporter (SERT ) inhibition and receptor modulation. This chapter deals with vortioxetine's discovery and development, and the impact that careful attention to engaging specific biological targets in the brain has played in its successful development. In drug discovery, in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies play a key role in ensuring that the drug-like properties and the developability potential are in place before the compound is advanced to the clinic.",
keywords = "Drug metabolism and pharmacokinetic (DMPK), Food and Drug Administration (FDA), Major depressive disorder (MDD), Multimodal acting antidepressant vortioxetine, Selective serotonin reuptake inhibitors (SSRIs)",
author = "Christoffer Bundgaard and Alan Pehrson and Connie S{\'a}nchez and Benny Bang-Andersen",
year = "2015",
month = "1",
day = "2",
doi = "10.1002/9781118788523.ch23",
language = "English",
isbn = "9781118788356",
pages = "505--520",
booktitle = "Blood-Brain Barrier in Drug Discovery",
publisher = "wiley",

}

Bundgaard, C, Pehrson, A, Sánchez, C & Bang-Andersen, B 2015, Case Study 2: The Discovery and Development of the Multimodal Acting Antidepressant Vortioxetine. in Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs. wiley, pp. 505-520. https://doi.org/10.1002/9781118788523.ch23

Case Study 2 : The Discovery and Development of the Multimodal Acting Antidepressant Vortioxetine. / Bundgaard, Christoffer; Pehrson, Alan; Sánchez, Connie; Bang-Andersen, Benny.

Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs. wiley, 2015. p. 505-520.

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

TY - CHAP

T1 - Case Study 2

T2 - The Discovery and Development of the Multimodal Acting Antidepressant Vortioxetine

AU - Bundgaard, Christoffer

AU - Pehrson, Alan

AU - Sánchez, Connie

AU - Bang-Andersen, Benny

PY - 2015/1/2

Y1 - 2015/1/2

N2 - Vortioxetine, which was approved by the Food and Drug Administration (FDA) on September 30, 2013, for treatment of major depressive disorder (MDD) originates from the line of research aiming at an enhanced therapeutic effect compared to selective serotonin reuptake inhibitors (SSRIs) through modulation of neuroadaptive feedback mechanisms. This research led to a new class of multimodal acting antidepressants, which act via serotonin transporter (SERT ) inhibition and receptor modulation. This chapter deals with vortioxetine's discovery and development, and the impact that careful attention to engaging specific biological targets in the brain has played in its successful development. In drug discovery, in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies play a key role in ensuring that the drug-like properties and the developability potential are in place before the compound is advanced to the clinic.

AB - Vortioxetine, which was approved by the Food and Drug Administration (FDA) on September 30, 2013, for treatment of major depressive disorder (MDD) originates from the line of research aiming at an enhanced therapeutic effect compared to selective serotonin reuptake inhibitors (SSRIs) through modulation of neuroadaptive feedback mechanisms. This research led to a new class of multimodal acting antidepressants, which act via serotonin transporter (SERT ) inhibition and receptor modulation. This chapter deals with vortioxetine's discovery and development, and the impact that careful attention to engaging specific biological targets in the brain has played in its successful development. In drug discovery, in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies play a key role in ensuring that the drug-like properties and the developability potential are in place before the compound is advanced to the clinic.

KW - Drug metabolism and pharmacokinetic (DMPK)

KW - Food and Drug Administration (FDA)

KW - Major depressive disorder (MDD)

KW - Multimodal acting antidepressant vortioxetine

KW - Selective serotonin reuptake inhibitors (SSRIs)

UR - http://www.scopus.com/inward/record.url?scp=85017341007&partnerID=8YFLogxK

U2 - 10.1002/9781118788523.ch23

DO - 10.1002/9781118788523.ch23

M3 - Chapter

SN - 9781118788356

SP - 505

EP - 520

BT - Blood-Brain Barrier in Drug Discovery

PB - wiley

ER -

Bundgaard C, Pehrson A, Sánchez C, Bang-Andersen B. Case Study 2: The Discovery and Development of the Multimodal Acting Antidepressant Vortioxetine. In Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs. wiley. 2015. p. 505-520 https://doi.org/10.1002/9781118788523.ch23